Skip to main content
Premium Trial:

Request an Annual Quote

Agilent, Applied Proteomics Partner on Development of Mass Spec-based Protein Assays

NEW YORK (GenomeWeb News) – Agilent Technologies and Applied Proteomics today announced a collaboration to develop multiplex protein assays and workflow solutions for multiple reaction monitoring (MRM) using mass spectrometry.

Applied Proteomics will use Agilent instruments, including the 6490 Triple Quadrupole MS/MS, 1290 Infinity LC, RapidFire 360 MS system, and Bravo liquid handling technologies to "optimize the throughput of highly multiplexed proteomic assays," the firms said.

Financial and other terms of the deal were not disclosed.

"The ability to quickly and accurately measure, monitor, and analyze a large number of protein biomarkers in a single test has important applications for understanding human diseases and developing new clinical diagnostics," Applied Proteomics Chief Science Officer John Blume said in a statement. "Agilent's innovation in mass spectrometry is an important part of this collaboration as we work together to expand the capabilities of multiplex protein assays."

Applied Proteomics has developed a platform that makes protein biomarker discovery "possible as a replicable, industrial application ready to be applied to health diagnostic problems," according to the company.

Last year it raised $22.5 million in a Series B financing round and moved its operations to San Diego.